Gilead Sciences, Inc. (GILD): Price and Financial Metrics
Gilead Sciences, Inc. (GILD)
Today's Latest Price: $67.38 USD
Updated Jan 19 11:58am
Add GILD to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
GILD Stock Summary
- GILD has a market capitalization of $79,385,937,676 -- more than approximately 97.23% of US stocks.
- With a price/earnings ratio of 62.61, Gilead Sciences Inc P/E ratio is greater than that of about 83.33% of stocks in our set with positive earnings.
- Of note is the ratio of Gilead Sciences Inc's sales and general administrative expense to its total operating expenses; only 15.87% of US stocks have a lower such ratio.
- Stocks that are quantitatively similar to GILD, based on their financial statements, market capitalization, and price volatility, are ATVI, BDX, ZTS, NTES, and ADI.
- GILD's SEC filings can be seen here. And to visit Gilead Sciences Inc's official web site, go to www.gilead.com.
GILD Stock Price Chart Interactive Chart >
GILD Price/Volume Stats
| Current price | $67.38 | 52-week high | $85.97 |
| Prev. close | $63.33 | 52-week low | $56.56 |
| Day low | $64.60 | Volume | 10,358,503 |
| Day high | $68.15 | Avg. volume | 10,380,159 |
| 50-day MA | $60.28 | Dividend yield | 4.29% |
| 200-day MA | $68.33 | Market Cap | 84.46B |
Gilead Sciences, Inc. (GILD) Company Bio
Gilead Sciences is a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs. The Company's primary areas of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.
GILD Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $67.38 | $27.71 | -56% |
We started the process of determining a valid price forecast for Gilead Sciences Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Gilead Sciences Inc ranked in the 33th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 56%. The most interesting components of our discounted cash flow analysis for Gilead Sciences Inc ended up being:
- The stock's equity weight, or the proportion of capital from equity relative to debt, is 73. Its equity weight surpasses that of just 24.78% of free cash flow generating stocks in the Healthcare sector.
- Its compound free cash flow growth rate, as measured over the past 5.5 years, is -0.12% -- higher than only 12.54% of stocks in our DCF forecasting set.
- Gilead Sciences Inc's weighted average cost of capital (WACC) is 8%; for context, that number is higher than merely 14.21% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -57% |
| 1% | -57% |
| 2% | -56% |
| 3% | -56% |
| 4% | -55% |
| 5% | -55% |
Want more companies with a valuation profile/forecast similar to that of Gilead Sciences Inc? See BIO, MD, A, BAX, and JNJ.
Loading social stream, please wait...